Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice
(Q45743776)
scientific article published in March 2000
scientific article published in March 2000
Language: